Unfazed by slow rollout, Nestlé buys out Aimmune and its peanut allergy med for $2.6B
After steadily tightening its grip on Aimmune Therapeutics over the past four years, Nestlé is swooping in to take full control.
The Swiss food and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
